Xu Y - Search Results

1

Diagnostic Accuracy of Artificial Intelligence Based on Imaging Data for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Zhang J, Huang S, Xu Y, Wu J. Zhang J, et al. Among authors: xu y. Front Oncol. 2022 Feb 24;12:763842. doi: 10.3389/fonc.2022.763842. eCollection 2022. Front Oncol. 2022. PMID: 35280776 Free PMC article.

2

The Prognostic Value of Lysine Acetylation Regulators in Hepatocellular Carcinoma.

Sun L, Zhang J, Wen K, Huang S, Li D, Xu Y, Wu J. Sun L, et al. Among authors: xu y. Front Mol Biosci. 2022 Mar 9;9:840412. doi: 10.3389/fmolb.2022.840412. eCollection 2022. Front Mol Biosci. 2022. PMID: 35355509 Free PMC article.

3

ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion.

Huang S, Dong C, Li D, Xu Y, Wu J. Huang S, et al. Among authors: xu y. Front Cell Dev Biol. 2022 Jun 6;10:896080. doi: 10.3389/fcell.2022.896080. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35733852 Free PMC article.

4

Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma.

Xu Y, Fu S, Mao Y, Huang S, Li D, Wu J. Xu Y, et al. Front Med (Lausanne). 2022 Sep 1;9:919069. doi: 10.3389/fmed.2022.919069. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36117969 Free PMC article.

5

PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib.

Xu Y, Fu S, Shang K, Zeng J, Mao Y. Xu Y, et al. Front Oncol. 2022 Sep 13;12:958869. doi: 10.3389/fonc.2022.958869. eCollection 2022. Front Oncol. 2022. PMID: 36176403 Free PMC article.

6

Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice.

Liu K, Wu J, Xu Y, Li D, Huang S, Mao Y. Liu K, et al. Among authors: xu y. Onco Targets Ther. 2022 Oct 1;15:1079-1094. doi: 10.2147/OTT.S383685. eCollection 2022. Onco Targets Ther. 2022. PMID: 36212725 Free PMC article.

7

CKLF as a Prognostic Biomarker and Its Association with Immune Infiltration in Hepatocellular Carcinoma.

Li D, Huang S, Luo C, Xu Y, Fu S, Liu K, Wu J. Li D, et al. Among authors: xu y. Curr Oncol. 2023 Feb 22;30(3):2653-2672. doi: 10.3390/curroncol30030202. Curr Oncol. 2023. PMID: 36975415 Free PMC article.

8

Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study.

Xu Y, Fu S, Liu K, Mao Y, Wu J. Xu Y, et al. Ther Clin Risk Manag. 2023 Oct 24;19:853-863. doi: 10.2147/TCRM.S420371. eCollection 2023. Ther Clin Risk Manag. 2023. PMID: 37899984 Free PMC article.

9

MicroRNA 211-5p inhibits cancer cell proliferation and migration in pancreatic cancer by targeting BMP2.

Li D, Luo C, Deng J, Xu Y, Fu S, Liu K, Wu J. Li D, et al. Among authors: xu y. Aging (Albany NY). 2023 Dec 6;15(23):14411-14421. doi: 10.18632/aging.205320. Epub 2023 Dec 6. Aging (Albany NY). 2023. PMID: 38059889 Free PMC article.

10

Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.

Fu S, Xu Y, Mao Y, He M, Chen Z, Huang S, Li D, Lv Y, Wu J. Fu S, et al. Among authors: xu y. Cancer Med. 2024 May;13(9):e7105. doi: 10.1002/cam4.7105. Cancer Med. 2024. PMID: 38686567 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73,573 results

Search Page

Filters